Predict your next investment

HEALTHCARE | Biotechnology
nanostring.com

See what CB Insights has to offer

Founded Year

2003

Stage

IPO | IPO

Total Raised

$104.64M

Date of IPO

6/26/2013

Market Cap

1.95B

Stock Price

41.62

Revenue

$0000 

About NanoString Technologies

NanoString Technologies is a provider of life science tools for translational research and developer of molecular diagnostics. The company's nCounter Analysis System delivers highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to profile gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company's technology enables a variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.In June 2013, NanoString Technologies went public with a valuation of $145 million.

NanoString Technologies Headquarter Location

530 Fairview Avenue North Suite 2000

Seattle, Washington, 98109,

United States

206-378-6266

Latest NanoString Technologies News

NanoString Launches NCounter TCR Diversity Panel And Analysis Package At The 2021 Annual Meeting Of The Society For Immunotherapy Of Cancer

Nov 11, 2021

Nov 11, 2021 6:00 AM EST NanoString Launches NCounter TCR Diversity Panel And Analysis Package At The 2021 Annual Meeting Of The Society For Immunotherapy Of Cancer NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® TCR Diversity Panel and companion cloud-based TCR analysis report created for use... Author: NanoString Technologies, Inc. ( NSTG ) - Get NanoString Technologies, Inc. Report , a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® TCR Diversity Panel and companion cloud-based TCR analysis report created for use with the ROSALIND® platform. This new gene expression panel allows researchers to measure the usage of T cell receptor (TCR) variable regions and shifts in TCR diversity with a simple assay that can deliver results in less than 24 hours. A diverse population of TCRs is a hallmark of a healthy immune system. The mix and abundance of TCR variable regions changes upon challenge with a pathogen, cancer, or any disease that triggers an adaptive immune response. TCRs are studied to understand disease onset, progression, response or non-response to treatment, and disease recovery. By directly quantifying the expression of each TCR variable region, the nCounter TCR Diversity Panel can rapidly screen samples without the time and cost of laborious sequencing methods. "The nCounter TCR Diversity Panel provides an intuitive, powerful new tool for use with clinical samples," said Dr. Léon van Kempen, an early access user and scientific lead at the Laboratory for Molecular Pathology at University Medical Center Groningen, Netherlands. "The panel allows for a TCR diversity score to be easily calculated based on expression and objectively quantifies a T cell response allowing for broad utility of the panel throughout all types of research." The new panel utilizes the unique oligonucleotide barcoding chemistry of the nCounter Analysis System to detect mRNA transcripts directly. It contains probes for 129 human genes covering all TCR alpha, beta, gamma, delta variable regions as well as constant regions. The panel also allows for customization with the ability for researchers to add in and measure unique TCRs of interest. This novel solution is coupled with an automated data analysis report purchased separately and accessible within the ROSALIND platform, allowing researchers to analyze results and generate TCR diversity scores within minutes. "We remain committed to developing innovative tools to advance our understanding of the human immune response. Leveraging the simplicity of the nCounter workflow makes it possible to gain broader insights with higher throughput," said Joseph Beechem, Ph.D., chief scientific officer, NanoString. "In the future, we expect to enable our GeoMx Digital Spatial Profiler to study TCRs spatially within tissues, providing an entirely new dimension of knowledge." Learn more about the nCounter TCR Diversity Panel and the latest scientific advances in the field of immuno-oncology using the nCounter and GeoMx® Digital Spatial Profiler platforms at the virtual symposium and booth #8 at the 36 th annual Society for Immunotherapy of Cancer (SITC) Conference. Virtual Symposium: " Quantifying T-cell receptor diversity via expression analysis" is on Friday, Nov. 12, from 1:00 - 1:30 pm EST. The symposium is an opportunity to talk with Dr. Léon van Kempen, a clinical scientist in molecular pathology, about getting started with the spatial biology revolution and the GeoMx Whole Transcriptome Atlas. In addition, this workshop will focus on the nCounter TCR Diversity Gene Expression Panel and a case study on the use of the panel for clinical research. About NanoString Technologies, Inc. NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,000 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 75 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com . NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005386/en/ By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NanoString Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NanoString Technologies is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

10,972 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

NanoString Technologies Patents

NanoString Technologies has filed 45 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2019

8/24/2021

Molecular biology, Biotechnology, Molecular biology techniques, Protein methods, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/11/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/24/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, Molecular biology techniques, Protein methods, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

NanoString Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NanoString Technologies Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.